Tags

Type your tag names separated by a space and hit enter

COVID-19 and Cardiovascular Disease.
Circulation. 2020 May 19; 141(20):1648-1655.Circ

Abstract

Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19.

Authors+Show Affiliations

Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.Department of Medicine, Division of Cardiology, Columbia University Vagelos College of Physicians and Surgeons, New York.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

32200663

Citation

Clerkin, Kevin J., et al. "COVID-19 and Cardiovascular Disease." Circulation, vol. 141, no. 20, 2020, pp. 1648-1655.
Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020;141(20):1648-1655.
Clerkin, K. J., Fried, J. A., Raikhelkar, J., Sayer, G., Griffin, J. M., Masoumi, A., Jain, S. S., Burkhoff, D., Kumaraiah, D., Rabbani, L., Schwartz, A., & Uriel, N. (2020). COVID-19 and Cardiovascular Disease. Circulation, 141(20), 1648-1655. https://doi.org/10.1161/CIRCULATIONAHA.120.046941
Clerkin KJ, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020 May 19;141(20):1648-1655. PubMed PMID: 32200663.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - COVID-19 and Cardiovascular Disease. AU - Clerkin,Kevin J, AU - Fried,Justin A, AU - Raikhelkar,Jayant, AU - Sayer,Gabriel, AU - Griffin,Jan M, AU - Masoumi,Amirali, AU - Jain,Sneha S, AU - Burkhoff,Daniel, AU - Kumaraiah,Deepa, AU - Rabbani,LeRoy, AU - Schwartz,Allan, AU - Uriel,Nir, Y1 - 2020/03/21/ PY - 2020/3/24/pubmed PY - 2020/5/23/medline PY - 2020/3/24/entrez KW - COVID-19 KW - cardiovascular diseases KW - pandemics KW - severe acute respiratory syndrome coronavirus 2 SP - 1648 EP - 1655 JF - Circulation JO - Circulation VL - 141 IS - 20 N2 - Coronavirus disease 2019 (COVID-19) is a global pandemic affecting 185 countries and >3 000 000 patients worldwide as of April 28, 2020. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2, which invades cells through the angiotensin-converting enzyme 2 receptor. Among patients with COVID-19, there is a high prevalence of cardiovascular disease, and >7% of patients experience myocardial injury from the infection (22% of critically ill patients). Although angiotensin-converting enzyme 2 serves as the portal for infection, the role of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers requires further investigation. COVID-19 poses a challenge for heart transplantation, affecting donor selection, immunosuppression, and posttransplant management. There are a number of promising therapies under active investigation to treat and prevent COVID-19. SN - 1524-4539 UR - https://www.unboundmedicine.com/medline/citation/32200663/COVID_19_and_Cardiovascular_Disease_ L2 - https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.120.046941?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -